SML3505
KP1339
≥98% (elemental analysis)
别名:
BOLD-100 without cesium, FFC14A sodium salt, IT-139, KP1019 sodium salt, IndazolH [trans-RuCl(4)-(Indazol)(2)] sodium salt, NKP1339, trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] sodium salt
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C14H12Cl4N4NaRu
化学文摘社编号:
分子量:
502.14
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (elemental analysis)
Form:
powder
Quality Segment
assay
≥98% (elemental analysis)
form
powder
color
, white to very dark grey
solubility
H2O: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
SMILES string
Cl[Ru-](Cl)(Cl)Cl.C1(C=CC=C2)=C2NN=C1.C3(C=CC=C4)=C4NN=C3.[Na+]
InChI
1S/2C7H6N2.4ClH.Na.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;;/h2*1-5H,(H,8,9);4*1H;;/q;;;;;;+1;+3/p-4
InChI key
WVVOCRYXBTVDRN-UHFFFAOYSA-J
Biochem/physiol Actions
KP1339 (KP1019 sodium) is a ruthenium-indazole complex-based anticancer agent that induces pronounced apoptosis in sensetive cancer cells (Capan1/HCT116/SW480/KB-3-1 IC50 by MTT assay = 44/50/145/170 µM) via ER homeostasis disruption and caspase 8 activation due to depletion of key cellular chaperones, including BiP/GRP78/HSPA5, in combination with enhanced protein damage. When administered in vivo, KP1339 exhibits anti-tumor efficacy in the murine SA-1 fibrosarcoma model (10.5, 21.0, 42.0 mg/150 µL/kg i.v.).
Ruthenium-indazole complex-based anticancer agent in cultures and in vivo via ER homeostasis disruption by depleting chaperones, including BiP/GRP78/HSPA5.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable